Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection

Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive and fatal disease with a median survival of 36 months. With the advent of genetic sequencing to identify individual genomic profiles and acquired tumor-specific pathways, targeted therapies have revolutionized cancer treatment,...

Descripción completa

Detalles Bibliográficos
Autores principales: LeVee, Alexis, Lin, Ching Ying, Posadas, Edwin, Figlin, Robert, Bhowmick, Neil A, Di Vizio, Dolores, Ellis, Leigh, Rosser, Charlos J, Freeman, Michael R, Theodorescu, Dan, Freedland, Stephen J, Gong, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450162/
https://www.ncbi.nlm.nih.gov/pubmed/34552338
http://dx.doi.org/10.2147/OTT.S315170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450162/
https://www.ncbi.nlm.nih.gov/pubmed/34552338
http://dx.doi.org/10.2147/OTT.S315170

Ejemplares similares